标签归档：ng

NG25

发表于由

NG25  纯度: 99.35%

NG25 是一种 TAK1 和 MAP4K2 的双抑制剂，IC50 值分别为 149 nM 和 21.7 nM。

NG25

NG25 Chemical Structure

CAS No. : 1315355-93-1

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ￥3387 In-stock
1 mg ￥950 In-stock
5 mg ￥2864 In-stock
10 mg ￥5115 In-stock
50 mg   询价  
100 mg   询价  

* Please select Quantity before adding items.

NG25 相关产品

•相关化合物库:

  • Bioactive Compound Library Plus
  • Immunology/Inflammation Compound Library
  • Kinase Inhibitor Library
  • MAPK Compound Library
  • Anti-Cancer Compound Library
  • Oxygen Sensing Compound Library
  • Anti-Breast Cancer Compound Library

生物活性

NG25 is a potent dual TAK1 and MAP4K2 inhibitor, with IC50s of 149 nM and 21.7 nM, respectively.

IC50 & Target

TAK1

149 nM (IC50)

MAP4K2

21.7 nM (IC50)

ZC1/HGK

3250 nM (IC50)

ZAK

698 nM (IC50)

RAF1

7590 nM (IC50)

ABL,ARG

75.2 nM (IC50)

GSK

56.4 nM (IC50)

Eph A2

773 nM (IC50)

Eph B2

672 nM (IC50)

Eph B4

999 nM (IC50)

FER

82.3 nM (IC50)

LYN

12.9 nM (IC50)

SRC

113 nM (IC50)

体外研究
(In Vitro)

NG25 is a potent dual TAK1 and MAP4K2 inhibitor, with IC50s of 149 nM and 21.7 nM, respectively. NG25 also potently suppresses several kinases such as LYN, CSK, FER, p38α, ABL,ARG and SRC, with IC50s of 12.9, 56.4, 82.3, 102, 75.2, and 113 nM, respectively[1]. NG25 is very potent suppressor of CpG B- or CpG A-stimulated secretion of IFNα and CL097-stimulated secretion of IFNβ, with complete inhibition by 400 nM[2]. NG25 treatment reduces cell viability of all tested breast cancer cell lines in a dose dependent manner. NG25 (2 μM) enhances the cytotoxic effect of Dox on breast cancer cells[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

537.58

Formula

C29H30F3N5O2
CAS 号

1315355-93-1
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : 50 mg/mL (93.01 mM; Need ultrasonic)

H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.8602 mL 9.3009 mL 18.6019 mL
5 mM 0.3720 mL 1.8602 mL 3.7204 mL
10 mM 0.1860 mL 0.9301 mL 1.8602 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂： 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.5 mg/mL (4.65 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (4.65 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂： 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: 2.5 mg/mL (4.65 mM); Suspended solution; Need ultrasonic

    此方案可获得 2.5 mg/mL (4.65 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
  • 3.

    请依序添加每种溶剂： 10% DMSO    90% corn oil

    Solubility: ≥ 2.5 mg/mL (4.65 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (4.65 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在 MCE 网站选购。
参考文献

  • [1]. Tan L, et al. Discovery of type II inhibitors of TGFβ-activated kinase 1 (TAK1) and mitogen-activated protein kinase kinase kinase kinase 2 (MAP4K2). J Med Chem. 2015 Jan 8;58(1):183-96.

    [2]. Pauls E, et al. Essential role for IKKβ in production of type 1 interferons by plasmacytoid dendritic cells. J Biol Chem. 2012 Jun 1;287(23):19216-28.

    [3]. Wang Z, et al. TAK1 inhibitor NG25 enhances doxorubicin-mediated apoptosis in breast cancer cells. Sci Rep. 2016 Sep 7;6:32737.
Kinase Assay
[2]

IRF7 is expressed in Escherichia coli as a glutathione S-transferase (GST) fusion protein with a PreScission proteinase cleavage site between the GST and the IRF7. The GST-IRF7 is captured on glutathione-Sepharose and IRF7 released from GST and glutathione-Sepharose by digestion with PreScission proteinase. His6-tagged IKKβ and TBK1 are expressed in their active phosphorylated forms in insect Sf21 cells and purified by affinity chromatography on nickel nitrilotriacetate-agarose. Active GST-IKKα is purchased from Millipore and assayed.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Assay
[2]

3.5×105 Gen2.2 cells or Flt3-DCs are incubated for 1 h in 96-well plates without or with the indicated concentrations of inhibitor, then stimulated with 1 μM CpG (type A or B) or 1 μg/mL of CL097 or R848. After 5 or 12 h the cell culture supernatants are collected, clarified by centrifugation, and frozen at −80°C until cytokine levels are analyzed. For cell viability assays, unstimulated cells are incubated for 12 h in the absence or presence of inhibitors. Cells are then fixed and the percentage of live cells analyzed by flow cytometry.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
参考文献

  • [1]. Tan L, et al. Discovery of type II inhibitors of TGFβ-activated kinase 1 (TAK1) and mitogen-activated protein kinase kinase kinase kinase 2 (MAP4K2). J Med Chem. 2015 Jan 8;58(1):183-96.

    [2]. Pauls E, et al. Essential role for IKKβ in production of type 1 interferons by plasmacytoid dendritic cells. J Biol Chem. 2012 Jun 1;287(23):19216-28.

    [3]. Wang Z, et al. TAK1 inhibitor NG25 enhances doxorubicin-mediated apoptosis in breast cancer cells. Sci Rep. 2016 Sep 7;6:32737.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

NG25

发表于由

NG25  纯度: 99.35%

NG25 是一种 TAK1 和 MAP4K2 的双抑制剂，IC50 值分别为 149 nM 和 21.7 nM。

NG25

NG25 Chemical Structure

CAS No. : 1315355-93-1

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ￥3387 In-stock
1 mg ￥950 In-stock
5 mg ￥2864 In-stock
10 mg ￥5115 In-stock
50 mg   询价  
100 mg   询价  

* Please select Quantity before adding items.

NG25 相关产品

•相关化合物库:

  • Bioactive Compound Library Plus
  • Immunology/Inflammation Compound Library
  • Kinase Inhibitor Library
  • MAPK Compound Library
  • Anti-Cancer Compound Library
  • Oxygen Sensing Compound Library
  • Anti-Breast Cancer Compound Library

生物活性

NG25 is a potent dual TAK1 and MAP4K2 inhibitor, with IC50s of 149 nM and 21.7 nM, respectively.

IC50 & Target

TAK1

149 nM (IC50)

MAP4K2

21.7 nM (IC50)

ZC1/HGK

3250 nM (IC50)

ZAK

698 nM (IC50)

RAF1

7590 nM (IC50)

ABL,ARG

75.2 nM (IC50)

GSK

56.4 nM (IC50)

Eph A2

773 nM (IC50)

Eph B2

672 nM (IC50)

Eph B4

999 nM (IC50)

FER

82.3 nM (IC50)

LYN

12.9 nM (IC50)

SRC

113 nM (IC50)

体外研究
(In Vitro)

NG25 is a potent dual TAK1 and MAP4K2 inhibitor, with IC50s of 149 nM and 21.7 nM, respectively. NG25 also potently suppresses several kinases such as LYN, CSK, FER, p38α, ABL,ARG and SRC, with IC50s of 12.9, 56.4, 82.3, 102, 75.2, and 113 nM, respectively[1]. NG25 is very potent suppressor of CpG B- or CpG A-stimulated secretion of IFNα and CL097-stimulated secretion of IFNβ, with complete inhibition by 400 nM[2]. NG25 treatment reduces cell viability of all tested breast cancer cell lines in a dose dependent manner. NG25 (2 μM) enhances the cytotoxic effect of Dox on breast cancer cells[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

537.58

Formula

C29H30F3N5O2
CAS 号

1315355-93-1
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : 50 mg/mL (93.01 mM; Need ultrasonic)

H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.8602 mL 9.3009 mL 18.6019 mL
5 mM 0.3720 mL 1.8602 mL 3.7204 mL
10 mM 0.1860 mL 0.9301 mL 1.8602 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂： 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.5 mg/mL (4.65 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (4.65 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂： 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: 2.5 mg/mL (4.65 mM); Suspended solution; Need ultrasonic

    此方案可获得 2.5 mg/mL (4.65 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
  • 3.

    请依序添加每种溶剂： 10% DMSO    90% corn oil

    Solubility: ≥ 2.5 mg/mL (4.65 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (4.65 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在 MCE 网站选购。
参考文献

  • [1]. Tan L, et al. Discovery of type II inhibitors of TGFβ-activated kinase 1 (TAK1) and mitogen-activated protein kinase kinase kinase kinase 2 (MAP4K2). J Med Chem. 2015 Jan 8;58(1):183-96.

    [2]. Pauls E, et al. Essential role for IKKβ in production of type 1 interferons by plasmacytoid dendritic cells. J Biol Chem. 2012 Jun 1;287(23):19216-28.

    [3]. Wang Z, et al. TAK1 inhibitor NG25 enhances doxorubicin-mediated apoptosis in breast cancer cells. Sci Rep. 2016 Sep 7;6:32737.
Kinase Assay
[2]

IRF7 is expressed in Escherichia coli as a glutathione S-transferase (GST) fusion protein with a PreScission proteinase cleavage site between the GST and the IRF7. The GST-IRF7 is captured on glutathione-Sepharose and IRF7 released from GST and glutathione-Sepharose by digestion with PreScission proteinase. His6-tagged IKKβ and TBK1 are expressed in their active phosphorylated forms in insect Sf21 cells and purified by affinity chromatography on nickel nitrilotriacetate-agarose. Active GST-IKKα is purchased from Millipore and assayed.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Assay
[2]

3.5×105 Gen2.2 cells or Flt3-DCs are incubated for 1 h in 96-well plates without or with the indicated concentrations of inhibitor, then stimulated with 1 μM CpG (type A or B) or 1 μg/mL of CL097 or R848. After 5 or 12 h the cell culture supernatants are collected, clarified by centrifugation, and frozen at −80°C until cytokine levels are analyzed. For cell viability assays, unstimulated cells are incubated for 12 h in the absence or presence of inhibitors. Cells are then fixed and the percentage of live cells analyzed by flow cytometry.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
参考文献

  • [1]. Tan L, et al. Discovery of type II inhibitors of TGFβ-activated kinase 1 (TAK1) and mitogen-activated protein kinase kinase kinase kinase 2 (MAP4K2). J Med Chem. 2015 Jan 8;58(1):183-96.

    [2]. Pauls E, et al. Essential role for IKKβ in production of type 1 interferons by plasmacytoid dendritic cells. J Biol Chem. 2012 Jun 1;287(23):19216-28.

    [3]. Wang Z, et al. TAK1 inhibitor NG25 enhances doxorubicin-mediated apoptosis in breast cancer cells. Sci Rep. 2016 Sep 7;6:32737.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

NG-012

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

NG-012 

NG-012 是神经生长因子 (NGF) 增强剂，可从 Penicillium verruculosum F-4542 的培养液中分离得到。在大鼠嗜铬细胞瘤细胞系 (PC12) 中，NG-012 可增强 NGF 诱导的神经突生长。

NG-012

NG-012 Chemical Structure

CAS No. : 141731-76-2

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

NG-012, potentiator of nerve growth factor (NGF), were isolated from the culture broth of Penicillium verruculosum F-4542. NG-012 potentiates the neurite outgrowth induced by NGF in rat pheochromocytoma cell line (PC12)[1].

分子量

662.64

Formula

C32H38O15
CAS 号

141731-76-2
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. M Ito, et al. NG-011 and NG-012, novel potentiators of nerve growth factor. II. The structure determination of NG-011 and NG-012. J Antibiot (Tokyo). 1992 Oct;45(10):1566-72.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

NG-012

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

NG-012 

NG-012 是神经生长因子 (NGF) 增强剂，可从 Penicillium verruculosum F-4542 的培养液中分离得到。在大鼠嗜铬细胞瘤细胞系 (PC12) 中，NG-012 可增强 NGF 诱导的神经突生长。

NG-012

NG-012 Chemical Structure

CAS No. : 141731-76-2

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

NG-012, potentiator of nerve growth factor (NGF), were isolated from the culture broth of Penicillium verruculosum F-4542. NG-012 potentiates the neurite outgrowth induced by NGF in rat pheochromocytoma cell line (PC12)[1].

分子量

662.64

Formula

C32H38O15
CAS 号

141731-76-2
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. M Ito, et al. NG-011 and NG-012, novel potentiators of nerve growth factor. II. The structure determination of NG-011 and NG-012. J Antibiot (Tokyo). 1992 Oct;45(10):1566-72.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

NG-012

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

NG-012 

NG-012 是神经生长因子 (NGF) 增强剂，可从 Penicillium verruculosum F-4542 的培养液中分离得到。在大鼠嗜铬细胞瘤细胞系 (PC12) 中，NG-012 可增强 NGF 诱导的神经突生长。

NG-012

NG-012 Chemical Structure

CAS No. : 141731-76-2

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

NG-012, potentiator of nerve growth factor (NGF), were isolated from the culture broth of Penicillium verruculosum F-4542. NG-012 potentiates the neurite outgrowth induced by NGF in rat pheochromocytoma cell line (PC12)[1].

分子量

662.64

Formula

C32H38O15
CAS 号

141731-76-2
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. M Ito, et al. NG-011 and NG-012, novel potentiators of nerve growth factor. II. The structure determination of NG-011 and NG-012. J Antibiot (Tokyo). 1992 Oct;45(10):1566-72.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Purvalanol B(Synonyms: NG 95)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Purvalanol B (Synonyms: NG 95) 纯度: ≥97.0%

Purvalanol B (NG 95) 是一种有效、选择性、可逆和 ATP 竞争性的 CDK 抑制剂，对 cdc2-cyclin B，CDK2-cyclin A，CDK2-cyclin E 的 IC50 值分别为 6 nM、6 nM、9 nM、6 nM 和 CDK5-p35，分别。 Purvalanol B 在一系列其他蛋白激酶 (IC50>1000 nM) 中显示出对 CDK 的选择性。Purvalanol B 抑制耐氯喹菌株 P. falciparum 的生长。

Purvalanol B(Synonyms: NG 95)

Purvalanol B Chemical Structure

CAS No. : 212844-54-7

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ￥820 In-stock
5 mg ￥740 In-stock
10 mg ￥990 In-stock
50 mg ￥2500 In-stock
100 mg   询价  
200 mg   询价  

* Please select Quantity before adding items.

Purvalanol B 相关产品

•相关化合物库:

  • Bioactive Compound Library Plus
  • Anti-Infection Compound Library
  • Cell Cycle/DNA Damage Compound Library
  • Kinase Inhibitor Library
  • Anti-Cancer Compound Library
  • Anti-Aging Compound Library
  • Anti-Breast Cancer Compound Library
  • Anti-Blood Cancer Compound Library
  • Antiparasitic Compound library

生物活性

Purvalanol B (NG 95) is a potent, selective, reversible and ATP-competitive inhibitor CDK, with IC50s of 6 nM, 6 nM, 9 nM, 6 nM for cdc2-cyclin B, CDK2-cyclin A, CDK2-cyclin E and CDK5-p35, respectively. Purvalanol B shows selectivity for CDK over a range of other protein kinases (IC50>1000 nM). Purvalanol B inhibits the growth a chloroquine-resistant strain of P. falciparum[1][1].

IC50 & Target[1]

cdc2/cyclin B

6 nM (IC50)

cdk2/cyclin A

6 nM (IC50)

CDK2/cyclinE

9 nM (IC50)

CDK5/p35

6 nM (IC50)

体外研究
(In Vitro)

Purvalanol B binds to P. falciparum casein kinase 1 (CK1) from blood stage cell lysates and inhibits the growth a chloroquine-resistant strain of P. falciparum (FCR-3) with an IC50 of 7.07 μM[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

432.90

Formula

C20H25ClN6O3
CAS 号

212844-54-7
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : ≥ 40 mg/mL (92.40 mM)

* “≥” means soluble, but saturation unknown.

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.3100 mL 11.5500 mL 23.1000 mL
5 mM 0.4620 mL 2.3100 mL 4.6200 mL
10 mM 0.2310 mL 1.1550 mL 2.3100 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂： 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.5 mg/mL (5.78 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (5.78 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂： 10% DMSO    90% corn oil

    Solubility: ≥ 2.5 mg/mL (5.78 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (5.78 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献

  • [1]. Gray NS, et, al. Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science. 1998 Jul 24;281(5376):533-8.

    [2]. Bullard KM, et, al. Effects of cyclin-dependent kinase inhibitor Purvalanol B application on protein expression and developmental progression in intra-erythrocytic Plasmodium falciparum parasites. Malar J. 2015 Apr 8;14:147.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

NG 012

发表于由

NG 012

一种新型的神经生长因子增强剂

有货

NG 012

CAS编号 141731-76-2 | 品牌：Jinpan
NG 012

MSDS

质检证书(CoA)

相似产品

  • 分子式 C32H38O15
  • 分子量662.64
  • PubChem编号 21774848

货号 (SKU) 包装规格 是否现货 价格 数量
N351678-1mg 1mg 期货 NG 012  
N351678-5mg 5mg 期货 NG 012  

基本信息

产品名称 NG 012
英文名称 NG 012
英文别名 Orbuticin derivative
运输条件 超低温冰袋运输

一般描述

神经生长因子（NGF）增强剂的一种新型形式。

A novel form of nerve growth factor (NGF) potentiator.

相关属性

CAS编号 141731-76-2
溶解性 Soluble in 100% ethanol, acetone, acetonitrile, chloroform, ethyl acetate or methanol. Insoluble in water or hexane.
储存温度 -20°C储存
分子量 662.64
分子式 C32H38O15
品牌 Jinpan
Smiles C[C@@H]1CC2=CC(=CC(=C2C(=O)O[C@@H](CC(=O)O[C@@H](CC(=O)O[C@@H](CC3=CC(=CC(=C3C(=O)O[C@@H](CC(=O)O1)C)O)O)C)CO)C)O)O
PubChem CID 21774848

NG 52(Synonyms: Compound 52)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

NG 52 (Synonyms: Compound 52) 纯度: 99.97%

NG 52 是一种有效的，选择性的 ATP 兼容且具有口服活性的 Cdc28p 和 Pho85p 激酶抑制剂，IC50 分别为 7 μM 和 2 μM。NG 52 还以 IC50 值为 2.5 μM 来抑制磷酸甘油酸激酶 1 (PGK1) 的活性。NG 52 对酵母激酶 Kin28p，Srb10 和 Cak1p 无活性。

NG 52(Synonyms: Compound 52)

NG 52 Chemical Structure

CAS No. : 212779-48-1

规格 价格 是否有货 数量
Free Sample (0.1-0.5 mg)   Apply now  
10 mM * 1 mL in DMSO ￥1596 In-stock
5 mg ￥1451 In-stock
10 mg ￥2604 In-stock
50 mg ￥7858 In-stock
100 mg ￥10230 In-stock
200 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

NG 52 相关产品

•相关化合物库:

  • Bioactive Compound Library Plus
  • Cell Cycle/DNA Damage Compound Library
  • Kinase Inhibitor Library
  • Anti-Cancer Compound Library
  • Anti-Aging Compound Library
  • Orally Active Compound Library
  • Anti-Breast Cancer Compound Library
  • Anti-Blood Cancer Compound Library

生物活性

NG 52 is a potent, cell-permeable, selective, ATP-compatible and orally active Cdc28p and Pho85p kinase inhibitor with IC50s of 7 μM and 2 μM, respectively. NG 52 also inhibits the activity of phosphoglycerate kinase 1 (PGK1) with an IC50 of 2.5 μM. NG 52 is inactive against yeast kinases Kin28p, Srb10, and Cak1p[1][2].

IC50 & Target[1][2]

cdc2-cyclin B

0.34 μM (IC50)

Pho85p

2 nM (IC50)

Cdc28p

7 μM (IC50)

Phosphoglycerate kinase 1 (PGK1)

2.5 μM (IC50)

体外研究
(In Vitro)

NG 52 (Compound 52) inhibits growth in a drug-sensitized yeast strain (S. cerevisiae) with a GI50 of 30 μM. NG 52 is active against cdc2-cyclin B with an IC50 value of 340 nM[1].
NG 52 dose-dependently inhibits the proliferation of glioma U87 and U251 cell lines with GI50 values of 7.8 μM and 5.2 μM, respectively, meanwhile it potently inhibits the proliferation of primary glioma cells[2].
NG 52 (12.5-50 μM) effectively inhibits the phosphorylation of PDHK1 at Thr338 site and the phosphorylation of PDH at Ser293 site in U87 and U251 cells, resulting in more pyruvic acid entering the Krebs cycle with increased production of ATP and ROS[2].
NG 52 can reverse the Warburg effect by enhancing the activity of pyruvate dehydrogenase (PDH) through inhibiting the activity of PGK1, and switched cellular glucose metabolism from anaerobic mode to aerobic mode[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay[2]

Cell Line: Glioma U87 and U251 cells
Concentration: 0 μM, 12.5 μM, 25 μM, 50 μM
Incubation Time: 6 days
Result: Potently inhibited the proliferation of primary glioma cells.

Western Blot Analysis[2]

Cell Line: Glioma U87 and U251 cells
Concentration: 0 μM, 12.5 μM, 25 μM, 50 μM
Incubation Time: 12 hours or 24 hours
Result: Potently inhibited the proliferation of primary glioma cells.

体内研究
(In Vivo)

NG 52 (50-150 mg/kg; oral administration; daily; for 13 days) treatment dose-dependently suppresses the growth of glioma xenograft[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Female nu/nu mice (5-week-old) injected with glioma cells[2]
Dosage: 50 mg/kg, 100 mg/kg, 150 mg/kg
Administration: Oral administration; daily; for 13 days
Result: Dose-dependently suppressed the growth of glioma xenograft.

分子量

346.81

Formula

C16H19ClN6O
CAS 号

212779-48-1
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : 100 mg/mL (288.34 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.8834 mL 14.4171 mL 28.8342 mL
5 mM 0.5767 mL 2.8834 mL 5.7668 mL
10 mM 0.2883 mL 1.4417 mL 2.8834 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂： 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.5 mg/mL (7.21 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (7.21 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂： 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.5 mg/mL (7.21 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (7.21 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
  • 3.

    请依序添加每种溶剂： 10% DMSO    90% corn oil

    Solubility: ≥ 2.5 mg/mL (7.21 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (7.21 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献

  • [1]. ray NS, Wodicka L, Thunnissen AM et al. Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science. 1998 Jul 24;281(5376):533-8.

    [2]. Wen-Liang Wang, et al. Pharmacologically inhibiting phosphoglycerate kinase 1 for glioma with NG52. Acta Pharmacol Sin. 2020 Jul 31.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务